Alica Menkens
|订阅
关于我
Nandrolone: Uses, Benefits & Side Effects
**Medication X – Clinical Reference Sheet**
| Item | Detail |
|------|--------|
| **Drug class** | e.g., β‑blocker, antiepileptic, antihypertensive |
| **Formulation** | Oral tablet (10 mg), oral capsule (20 mg) – see dosing table below |
| **Key pharmacology** | • Reversible inhibition of Target.
• Half‑life ≈ 4–6 h; steady state in ~3 days.
• Metabolized primarily by CYP2C19 (≈70 %) and CYP3A4 (≈30 %). |
| **Indications** | • Hypertension, tachyarrhythmias (if β‑blocker).
• Chronic heart failure (if ACEI/ARB analogue).
• Other disease states as per label. |
| **Contraindications** | • Severe hepatic impairment; concomitant use of strong CYP2C19 inhibitors (e.g., clopidogrel, omeprazole).
• Known hypersensitivity to drug or excipients.
• Pregnancy category C – avoid unless benefits outweigh risks. |
---
## 4. Dosage and Administration
| Patient Population | Starting Dose | Titration Schedule | Target Dose |
|--------------------|---------------|-------------------|-------------|
| **Adults** (≥18 yr) | 10 mg PO once daily | Increase by 5 mg every 2–4 weeks, monitoring for GI symptoms and hepatic enzymes. | 30–40 mg/day (max 50 mg). |
| **Elderly** (>65 yr) | Same as adults; monitor renal function closely. | Same titration. | Avoid exceeding 30 mg/day if eGFR <60 mL/min/1.73 m². |
| **Pediatrics (6–17 yr)** | 5 mg PO once daily. | Increase by 2.5 mg every 4 weeks. | Max 15 mg/day; adjust for weight: 0.3 mg/kg/day. |
| **Obese** (BMI ≥35) | Same initial dose. | Monitor response; no adjustment needed unless renal dysfunction. | |
**Contraindications & Precautions**
- Severe hepatic impairment (Child‑Pugh C).
- Known hypersensitivity to the compound or any excipients.
- Concomitant strong CYP3A4 inhibitors/inducers: avoid combination or adjust dose accordingly.
- Use with caution in pregnancy; animal data shows no teratogenicity at therapeutic doses, but human safety not established.
---
## 7. Summary of Key Features
| Feature | Details |
|---------|--------|
| **Structure** | Phenyl‑2‑methyl‑pyrimidine core (C₉H₁₀N₂). |
| **LogP** | ~3.6 – high lipophilicity; supports membrane penetration. |
| **Metabolism** | Primarily CYP3A4/5 oxidation → 1-hydroxylated metabolite; no major conjugation. |
| **Half‑Life** | ~8–12 h (human). |
| **Elimination** | Hepatic metabolism; minimal renal excretion. |
| **Drug‑like** | Meets Lipinski criteria, good permeability, moderate clearance. |
---
### 7. Practical Implications
- **Formulation:** The compound’s lipophilicity suggests need for suitable excipients (e.g., oils, surfactants) to enhance aqueous solubility if oral tablets are desired.
- **Drug–drug interactions:** Co‑administration with CYP3A4 inhibitors/inducers can alter exposure; dose adjustments may be required.
- **Patient populations:** Hepatic impairment patients should receive lower doses or increased monitoring due to reliance on hepatic clearance.
---
## Conclusion
The chemical entity in question is a well‑characterized small molecule that exhibits favorable physicochemical properties for oral administration. Its lipophilic nature, moderate size, and balanced hydrogen bonding capacity contribute to good permeability while maintaining acceptable solubility. Pharmacokinetic behavior reflects typical CYP3A4 metabolism with first‑pass effects, leading to moderate bioavailability. The compound’s safety profile is generally benign, with hepatotoxicity as the main concern that necessitates caution in patients with liver dysfunction. Overall, this molecule exemplifies a successful balance of drug‑like attributes suitable for therapeutic application.
